Source:http://linkedlifedata.com/resource/pubmed/id/19010905
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
22
|
pubmed:dateCreated |
2008-11-17
|
pubmed:abstractText |
7-Ethyl-10-hydroxy-camptothecin (SN-38), an active metabolite of irinotecan hydrochloride (CPT-11), has potent antitumor activity. Moreover, we have reported the strong antitumor activity of NK012 (i.e., SN-38-releasing polymeric micelles) against human cancer xenografts compared with CPT-11. Here, we investigated the advantages of NK012 over CPT-11 treatment in mouse models of gastric cancer with peritoneal dissemination. NK012 or CPT-11 was i.v. administered thrice every 4 days at their respective maximum tolerable doses (NK012, 30 mg/kg/day; CPT-11, 67 mg/kg/day) to mice receiving orthotopic transplants of gastric cancer cell lines (44As3Luc and 58As1mLuc) transfected with the luciferase gene (n = 5). Antitumor effect was evaluated using the photon counting technique. SN-38 concentration in gastric tumors and peritoneal nodules was examined by high-performance liquid chromatography (HPLC) 1, 24, and 72 hours after each drug injection. NK012 or CPT-11 distribution in these tumors was evaluated using a fluorescence microscope on the same schedule. In both models, the antitumor activity of NK012 was superior to that of CPT-11. High concentrations of SN-38 released from NK012 were detected in gastric tumors and peritoneal nodules up to 72 hours by HPLC. Only a slight conversion from CPT-11 to SN-38 was observed from 1 to 24 hours. Fluorescence originating from NK012 was detected up to 72 hours, whereas that from CPT-11 disappeared until 24 hours. NK012 also showed antitumor activity against peritoneal nodules. Thus, NK012 showing enhanced distribution with prolonged SN-38 release may be ideal for cancer treatment because the antitumor activity of SN-38 is time dependent.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
1538-7445
|
pubmed:author |
pubmed-author:HamaguchiTetsuyaT,
pubmed-author:KatoKenK,
pubmed-author:MatsumuraYasuhiroY,
pubmed-author:MiharaKeichiroK,
pubmed-author:NakajimaTakako EguchiTE,
pubmed-author:OchiyaTakahiroT,
pubmed-author:ShimadaYasuhiroY,
pubmed-author:TakigahiraMisatoM,
pubmed-author:YamadaYasuhideY,
pubmed-author:YanagiharaKazuyoshiK,
pubmed-author:YasunagaMasahiroM
|
pubmed:issnType |
Electronic
|
pubmed:day |
15
|
pubmed:volume |
68
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
9318-22
|
pubmed:dateRevised |
2008-12-23
|
pubmed:meshHeading |
pubmed-meshheading:19010905-Animals,
pubmed-meshheading:19010905-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:19010905-Camptothecin,
pubmed-meshheading:19010905-Cell Line, Tumor,
pubmed-meshheading:19010905-Female,
pubmed-meshheading:19010905-Humans,
pubmed-meshheading:19010905-Mice,
pubmed-meshheading:19010905-Mice, Inbred BALB C,
pubmed-meshheading:19010905-Micelles,
pubmed-meshheading:19010905-Microscopy, Fluorescence,
pubmed-meshheading:19010905-Peritoneal Neoplasms,
pubmed-meshheading:19010905-Stomach Neoplasms,
pubmed-meshheading:19010905-Tissue Distribution
|
pubmed:year |
2008
|
pubmed:articleTitle |
Antitumor effect of SN-38-releasing polymeric micelles, NK012, on spontaneous peritoneal metastases from orthotopic gastric cancer in mice compared with irinotecan.
|
pubmed:affiliation |
Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|